[HTML][HTML] Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes
T John, A Taylor, H Wang, C Eichinger, C Freeman… - Cancer …, 2022 - Elsevier
Mutations in exons 18–21 of the epidermal growth factor receptor gene (EGFR) can confer
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …
[HTML][HTML] Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI …
Background The mechanism of primary resistance to epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small-cell lung cancer …
(EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small-cell lung cancer …
Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer
Y Kashima, D Shibahara, A Suzuki, K Muto… - Cancer research, 2021 - AACR
Tumor heterogeneity underlies resistance to tyrosine kinase inhibitors (TKI) in lung cancers
harboring EGFR mutations. Previous evidence suggested that subsets of preexisting …
harboring EGFR mutations. Previous evidence suggested that subsets of preexisting …
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms
C Proto, GL Russo, G Corrao, M Ganzinelli… - Tumori …, 2017 - journals.sagepub.com
In non-small cell lung cancer (NSCLC), the identification of epidermal growth factor receptor
(EGFR) mutations and the parallel development of EGFR tyrosine kinase inhibitors (TKIs) …
(EGFR) mutations and the parallel development of EGFR tyrosine kinase inhibitors (TKIs) …
[HTML][HTML] Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation …
E Santoni-Rugiu, M Grauslund, LC Melchior, JC Costa… - Lung Cancer, 2017 - Elsevier
Patients with epidermal growth factor receptor (EGFR) gene-mutated non-small cell lung
cancer (NSCLC) obtain substantial clinical benefit from EGFR tyrosine-kinase inhibitors …
cancer (NSCLC) obtain substantial clinical benefit from EGFR tyrosine-kinase inhibitors …
Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation
Z Lian, W Du, Y Zhang, Y Fu, T Liu, A Wang… - Thoracic …, 2020 - Wiley Online Library
Background Although many studies have defined mechanisms of resistance to EGFR‐TKIs,
acquired resistance remains the major limitation of monotherapy with EGFR‐TKIs. Methods …
acquired resistance remains the major limitation of monotherapy with EGFR‐TKIs. Methods …
[HTML][HTML] Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors
S Kobayashi, HM Canepa, AS Bailey… - Journal of Thoracic …, 2013 - Elsevier
Background: Non–small-cell lung cancers (NSCLCs) containing EGFR mutations are
exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …
exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …
[HTML][HTML] Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells
K Furugaki, T Iwai, Y Moriya, N Harada… - Lung Cancer, 2014 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show notable
effects against non-small cell lung cancers (NSCLCs) harboring EGFR-activating mutations …
effects against non-small cell lung cancers (NSCLCs) harboring EGFR-activating mutations …
Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation
T Guo, L Zhu, W Li, R Lin, Y Ding, Q Kang, L Shao, C Li… - Lung Cancer, 2021 - Elsevier
The development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) has revolutionized the treatment for non-small cell lung cancer (NSCLC) …
(TKIs) has revolutionized the treatment for non-small cell lung cancer (NSCLC) …
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib
Y Xu, H Liu, J Chen, Q Zhou - Cancer biology & therapy, 2010 - Taylor & Francis
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …